HSA
KRYS icon

Hussman Strategic Advisors’s Krystal Biotech KRYS Stock Holding History

Hussman Strategic Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,200
Closed -$658K – 290
2024
Q4 		$658K Buy
+4,200
New +$745K 0.19% 172

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Hussman Strategic Advisors's KRYS Position: Q1 2025 in Review

Hussman Strategic Advisors sold out of Krystal Biotech (KRYS) in Q1 2025, closing a stake of 4,200 shares — an estimated $658K sold.

Hussman Strategic Advisors first reported a position in KRYS in Q4 2024 and held it in 1 quarter. The position peaked at $658K in Q4 2024. 299 funds tracked by Wall St. Rank hold KRYS as of Q1 2025.

  • Hussman Strategic Advisors reported no remaining Krystal Biotech position as of Q1 2025 after selling out during the quarter.
  • Hussman Strategic Advisors sold 4,200 Krystal Biotech shares in Q1 2025, an estimated $658K.
  • Hussman Strategic Advisors first reported a position in Krystal Biotech in Q4 2024 and held it in 1 quarter.
  • Hussman Strategic Advisors's Krystal Biotech position peaked at $658K in Q4 2024.
  • 299 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2025.

Based on Hussman Strategic Advisors's 13F filing for Q1 2025, filed 5 May 2025.